Recent Finacing
Recent Raise
Ariceum Therapeutics is a clinical-stage radiopharmaceutical company developing satoreotide, an SST2 receptor antagonist theranostic for diagnosis and treatment of SST2-expressing tumors, including neuroendocrine and small-cell lung cancers.
